• Explore /
  • Poster
  • / First-line sunitinib versus pazopanib in metastatic renal cell carcinoma (mRCC): Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).

First-line sunitinib versus pazopanib in metastatic renal cell carcinoma (mRCC): Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).

Abstract Poster

Authors

Jose Ruiz-Morales

Jose Manuel Ruiz Morales

Tom Baker Cancer Centre - University of Calgary, Calgary, AB, Canada

Jose Manuel Ruiz Morales , J Connor Wells , Frede Donskov , Georg A. Bjarnason , Jae-Lyun Lee , Jennifer J. Knox , Benoit Beuselinck , Ulka N. Vaishampayan , James Brugarolas , Reuben James Broom , Aristotelis Bamias , Takeshi Yuasa , Sandhya Srinivas , D. Scott Ernst , Carmel Jo Pezaro , Lori Wood , Christian K. Kollmannsberger , Brian I. Rini , Toni K. Choueiri , Daniel Yick Chin Heng

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2016 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session C: Renal Cell Cancer

Track

Renal Cell Cancer

Sub Track

Renal Cell Cancer

Citation

J Clin Oncol 34, 2016 (suppl 2S; abstr 544)

DOI

10.1200/jco.2016.34.2_suppl.544

Abstract #

544

Poster Bd #

F5

Abstract Disclosures

Similar Posters

First Author: Jose Manuel Ruiz Morales

Poster

2022 ASCO Genitourinary Cancers Symposium

Characterizing IMDC prognostic groups in contemporary first-line combination therapies for metastatic renal cell carcinoma (mRCC).

Characterizing IMDC prognostic groups in contemporary first-line combination therapies for metastatic renal cell carcinoma (mRCC).

First Author: Matthew Scott Ernst

First Author: Giuseppe Procopio

First Author: Shaan Dudani